Form 4: Regulus Therapeutics Executive Preston Klassen Acquires Shares Through RSU Vesting

Preston Klassen, President & Head of R&D at Regulus Therapeutics, acquired 67,500 shares of common stock due to the vesting of performance-based Restricted Stock Units (RSUs).

Summary

• Preston Klassen, a director and officer at Regulus Therapeutics, acquired 67,500 shares of common stock on January 9, 2025.
• The shares were acquired through the vesting of Restricted Stock Units (RSUs).
• 37,500 shares vested from an RSU grant on August 10, 2023, at a price of $1.36 per share.
• 30,000 shares vested from an RSU grant on January 12, 2024, at a price of $1.30 per share.
• The RSUs vested upon achievement of specific performance-based milestones, with 50% vesting immediately and the remaining 50% vesting one year later, subject to continued service.

Sentiment

Score: 7

Explanation: The document reflects a positive event (vesting of RSUs due to performance milestones) and indicates confidence from a key executive. However, it is a routine filing and does not contain any major news that would significantly impact the company's outlook.

Positives

• The vesting of RSUs indicates that performance milestones were met, which is a positive sign for the company's progress.
• The acquisition of shares by a key executive demonstrates confidence in the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the biotechnology industry where equity compensation is a significant part of executive pay. The vesting of RSUs is tied to performance, which aligns executive interests with company goals.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as part of executive compensation is a standard practice in the biotechnology industry, similar to companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals.
• The vesting of RSUs upon achievement of performance milestones is also a common practice, aligning executive compensation with company performance, similar to practices at companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals.
• The specific vesting terms (50% immediately upon milestone achievement and 50% one year later) are within the typical range observed in the industry.

Stakeholder Impact

• The vesting of RSUs is a positive signal for shareholders, indicating that performance goals are being met.
• The acquisition of shares by a key executive may increase investor confidence.

Key Dates

Keywords

Regulus Therapeutics, Preston Klassen, Restricted Stock Units, RSU, Share Acquisition, Vesting, Performance Milestones, Insider Trading, SEC Form 4